论文部分内容阅读
目的探讨PI3K-AKT信号通路分子CD44、TRIM24、TAGLN-2、ER、PR在乳腺浸润性导管癌中的表达及其临床意义。方法应用免疫组化EnVision两步法检测73例乳腺浸润性导管癌组织中CD44、TRIM24、TAGLN-2、ER、PR的表达,分析其与临床病理特征的关系及表达的相关性。结果 CD44、TRIM24、TAGLN-2、ER、PR的表达与患者年龄、肿瘤大小、组织学分级及淋巴结转移无明显相关性。CD44与TAGLN-2表达呈正相关(r=0.311,P=0.007);TRIM24与TAGLN-2表达呈正相关(r=0.421,P=0.000);CD44与ER表达呈负相关(r=-0.285,P=0.015);ER与PR表达呈正相关(r=0.598,P=0.000)。CD44阳性组患者术后5年累积生存率低于CD44阴性组(P=0.002);ER阳性组患者术后5年累积生存率高于ER阴性组(P=0.026)。结论在乳腺癌中CD44、TRIM24可能通过激活PI3K-AKT信号通路上调TAGLN-2表达,CD44可能通过激活PI3KAKT信号通路下调ER表达。CD44、ER有望成为预测乳腺浸润性导管癌患者预后的辅助因子,联合检测CD44、ER、PR的表达有助于乳腺浸润性导管癌治疗策略的选择及优化。
Objective To investigate the expression of PI3K-AKT signaling molecules CD44, TRIM24, TAGLN-2, ER and PR in invasive ductal carcinoma of the breast and its clinical significance. Methods The expressions of CD44, TRIM24, TAGLN-2, ER and PR in 73 cases of breast invasive ductal carcinoma were detected by immunohistochemical EnVision two-step method. The relationship between CD44, TRIM24, TAGLN- Results There was no significant correlation between the expression of CD44, TRIM24, TAGLN-2, ER and PR in patients with age, tumor size, histological grade and lymph node metastasis. There was a positive correlation between the expression of CD44 and TAGLN-2 (r = 0.311, P = 0.007). There was a positive correlation between TRIM24 and TAGLN-2 (r = 0.421, = 0.015). There was a positive correlation between ER and PR expression (r = 0.598, P = 0.000). The 5-year cumulative survival rate of patients with CD44 positive was lower than that of CD44 negative patients (P = 0.002). The 5-year cumulative survival rate of patients with positive ER was higher than that of ER negative patients (P = 0.026). Conclusion CD44 and TRIM24 may up-regulate TAGLN-2 expression in breast cancer by activating PI3K-AKT signaling pathway. CD44 may down-regulate ER expression by activating PI3KAKT signaling pathway. CD44 and ER are expected to be the cofactors for predicting the prognosis of patients with invasive ductal carcinoma of the breast. The combined detection of CD44, ER and PR expression is helpful for the selection and optimization of the treatment strategies for invasive ductal carcinoma of the breast.